<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2022-04-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001716947</issuerCik>
        <issuerName>Ensysce Biosciences, Inc.</issuerName>
        <issuerTradingSymbol>ENSC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001926732</rptOwnerCik>
            <rptOwnerName>Osman Nilab</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ENSYSCE BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>7946 IVANHOE AVENUE, SUITE 201</rptOwnerStreet2>
            <rptOwnerCity>LA JOLLA</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92037</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.07</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-04-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>200000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On April 18, 2022, Dr. Osman appointed Chief Medical Officer of Ensysce Biosciences, Inc. In connection with her employment, on April 18, 2022, Dr. Osman was granted an option (the &quot;Stock Option&quot;) to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc., par value $0.0001 per share, with an exercise price of $1.07. Twenty-five percent of the Stock Option is scheduled to vest on April 18, 2023, with the remaining shares vesting in equal monthly installments over the thirty-six months thereafter.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/Osman Nilab</signatureName>
        <signatureDate>2022-04-28</signatureDate>
    </ownerSignature>
</ownershipDocument>
